<DOC>
	<DOCNO>NCT02293018</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic property topically apply MTC896 Gel follow application 0.75 % ( w/w ) MTC896 Gel daily twice daily 1.5 % ( w/w ) daily 4 week treatment acne .</brief_summary>
	<brief_title>Pharmacokinetic Study MTC896 Gel Subjects With Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Is male nonpregnant female least 18 year age time screen ; 2 . Has provide write informed consent ( include consent photograph ) take Baseline , EOT , EOS visit ; 3 . Has casual level ( CL ) sebum ≥ 150 μg/cm2 forehead measure Sebumeter® ; 4 . Has SER ≥ 150 μg/cm2/h forehead measure Sebumeter® ; 5 . Has diagnose inflammatory acne vulgaris mild moderate severity define : At least 20 inflammatory lesion , At least 20 noninflammatory lesion , Investigator Global Assessment 2 great ; 6 . Is willing comply requirement protocol ; 7 . If female childbearing potential , negative urine/serum pregnancy test Screening Baseline/Day 1 willing use effective contraception study . Females consider childbearing potential unless surgically sterilize ( hysterectomy , bilateral oophorectomy , tubal ligation ) , diagnose infertile , sex partner vasectomize male partner , postmenopausal least 1 year , abstinent ; ( Acceptable method birth control define : abstinence , oral contraceptive , contraceptive patches/implants ; DepoProvera® , double barrier method ( eg , condom spermicide ) IUD . Birth control method must stable/unchanged 12 week prior Baseline must remain unchanged study participation ) ; 8 . If male , vasectomized agrees use accepted method birth control female partner study participation 30 day last study drug application ; 9 . Is good health free disease , opinion Investigator , would put subject risk participate study ; 10 . Is free systemic dermatologic disorder , , opinion Investigator , interfere study result increase risk adverse event ; 11 . Is willing abstain use facial treatment product personal care product ( moisturizer , sunscreen , hair spray , etc ) face study ; 12 . Is willing avoid sun exposure protect face hat/visor ; 13 . If male , must agree shave treatment area must agree alter routine shave regimen duration study ; 14 . Is willing refrain use treatment , study medication , include antibiotic , acne present face . Topical acne treatment significant measurable systemic absorption ( eg , benzoyl peroxide , salicylic acid ) allow treatment acne back , shoulder , chest ; 1 . Pregnant lactating plan become pregnant within 1 month study completion ; 2 . Known allergy/sensitivity drug product component ; 3 . Any skin condition may interfere evaluation safety acne vulgaris ( eg , rosacea ; seborrheic dermatitis ; perioral dermatitis ; corticosteroidinduced acne folliculitis ) ; 4 . Excessive facial hair would interfere diagnosis assessment acne vulgaris ; 5 . Excessive sun exposure , opinion Investigator , use tanning booth ; 6 . Active cystic acne acne congoblata , acne fulminans , secondary acne ; 7 . Two active nodular lesion ; 8 . Screening clinical chemistry hematology laboratory value consider clinically significant , opinion Investigator ; 9 . Participation investigational drug study within 30 day prior Screening ; 10 . Are poor medical risk systemic disease active uncontrolled infection , opinion Investigator ; 11 . Any condition , judgment Investigator , would put subject unacceptable risk participation study ; 12 . Treatment Cytochrome P450 3A4 ( CYP3A4 ) Cytochrome P450 3A5 ( CYP3A5 ) inhibitor ; 13 . Treatment overthecounter ( OTC ) topical medication treatment acne vulgaris include benzoyl peroxide , topical antiinflammatory medication , corticosteroid , αhydroxy/glycolic acid face within 2 week prior Baseline ; 14 . Treatment systemic corticosteroid ( include intranasal inhaled corticosteroid ) within 4 week prior Baseline ; 15 . Treatment systemic antibiotic systemic antiacne drug systemic antiinflammatory drug within 4 week prior Baseline ; 16 . Prescription topical retinoid use face within 4 week Baseline ( eg , tretinoin , tazarotene , adapalene ) ; 17 . Initiation treatment hormonal therapy dose change hormonal therapy within 12 week prior Baseline . Dose frequency use hormonal therapy start 12 week prior Baseline must remain unchanged throughout study . Hormonal therapy include , limited , testosterone , anabolic steroid , estrogenic progestational agent birth control pill ; 18 . Use androgen receptor blocker ( spironolactone flutamide ) within 3 month prior Baseline ; 19 . Oral retinoid use ( eg , isotretinoin ) within 9 month prior Baseline vitamin A supplement great 10,000 units/day within 6 month Baseline ; 20 . Facial procedure ( chemical laser peel , microdermabrasion , etc . ) within past 8 week study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>